fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Thioguanine

All products: general benefit

Lanvis · DIN 00282081 · 40 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
No interchangeable product listed in the Ontario extract
Lanvis · DIN 00282081 Manufacturer: Aspen Pharma Trading Limited; listing date 1996-10-01 Health Canada: Marketed since 2020-07-10 · brand LANVIS · ATC L01BB03 TIOGUANINE · form Tablet · route Oral · ingredients THIOGUANINE 40 MG · company Aspen pharmacare canada inc. · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Lanvis: Formulary list price $6.74 per unit (the source does not state the unit; exact figure $6.7412). What the ministry pays, not the patient.

Ministry pays: $6.7412 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00282081)

Source record
DIN 00282081: Lanvis Raw flags: sec3=Y Item: 100000023; group id 187; item number 0341; lccId None; manufacturer id ASN Source form: Tab; strength: 40mg Recorded listing: General benefit Source prices (unrounded): $6.7412; ministry $6.7412 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00282081 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=1812
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00282081
Shortage record checked October 6, 2026

Other products in the same Health Canada class (L01B, L01BB): coverage varies; not interchangeable

  • Mercaptopurine (Purinethol): general benefit
  • Fludarabine (Fludara): limited Use 424, 379
  • Capecitabine (Xeloda): general benefit
  • Fluorouracil + salicylic acid (Actikerall): general benefit
  • Methotrexate (Methotrexate Sodium): general benefit, not a benefit
Other drugs in the same formulary class (10:00 ANTINEOPLASTIC AGENTS) and how they are covered

Matched class: 10:00 ANTINEOPLASTIC AGENTS

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ABIRATERONE ACETATE, ALTRETAMINE, ANASTROZOLE, BUSERELIN ACETATE, BUSULFAN, CAPECITABINE, CHLORAMBUCIL, CYPROTERONE ACETATE, DAUNORUBICIN, DEGARELIX ACETATE, ETOPOSIDE, EXEMESTANE, FLUOROURACIL & SALICYLIC ACID, FULVESTRANT, GOSERELIN ACETATE, HYDROXYUREA, IMATINIB MESYLATE, LETROZOLE, LEUPROLIDE ACETATE, MELPHALAN, MERCAPTOPURINE, MITOTANE, PROCARBAZINE HCL, TEMOZOLOMIDE, TRIPTORELIN PAMOATE Some products covered without a code (check the product listing): BICALUTAMIDE, CYCLOPHOSPHAMIDE, FLUTAMIDE, LOMUSTINE (CCNU), MEGESTROL ACETATE, METHOTREXATE, TAMOXIFEN CITRATE, VINCRISTINE SULFATE 10:00 ANTINEOPLASTIC AGENTS

MERCAPTOPURINE

· 2 products · General benefit · strengths: 50mg · Tab

FLUDARABINE PHOSPHATE

· 1 products · Limited Use, codes 424, 379 · strengths: 10mg · Tab

CAPECITABINE

· 15 products · General benefit · strengths: 150mg, 500mg · Tab

FLUOROURACIL & SALICYLIC ACID

· 1 products · General benefit · strengths: 0.5% w/w & 10% w/w · Top Sol

METHOTREXATE

· 34 products · General benefit (29), Listed, not a benefit (1), Off-Formulary Interchangeable, not an ODB benefit (4) · strengths: 20mg/2mL, 50mg/2mL, 10mg/0.2mL, 12.5mg/0.25mL, 15mg/0.3mL, 17.5mg/0.35mL, 20mg/0.4mL, 22.5mg/0.45mL, 25mg/0.5mL, 2.5mg, 10mg · Inj Sol-2mL Pk, Inj Sol-Pref Syr, Tab

ABIRATERONE ACETATE

· 18 products · General benefit · strengths: 250mg, 500mg · Tab

ALTRETAMINE

· 1 products · General benefit · strengths: 50mg · Cap

ANASTROZOLE

· 18 products · General benefit · strengths: 1mg · Tab

BICALUTAMIDE

· 9 products · Listed, not a benefit (1), General benefit (8) · strengths: 50mg · Tab

BUSERELIN ACETATE

· 4 products · General benefit · strengths: 6.3mg, 9.45mg, 1mg/mL · Implant Kit, Inj Sol-5.5mL Pk, Nas Sp-10mL Pk

BUSULFAN

· 1 products · General benefit · strengths: 2mg · Tab

CHLORAMBUCIL

· 1 products · General benefit · strengths: 2mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 10:00 and 34 more
Full class listing Related classes: Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS LANVIS® (thioguanine) is indicated for: • the treatment of acute leukaemia. LANVIS is not recommended for maintenance therapy or similar long-term continuous treatments due to the high risk of liver toxicity. 1.1 Pediatrics Pediatrics (≤ 18 years of age): Liver toxicity has been observed in a high proportion of children receiving LANVIS as part of maintenance therapy. See 7.1.3 Pediatrics. 1.2 Geriatrics Geriatrics (≥ 65 years of age): Clinical studies of LANVIS did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently than younger subjects. See 7.1.4 Geriatrics. https://pdf.hres.ca/dpd_pm/00073846.PDF PM date: December 14, 2023 Source product: LANVIS; DIN 00282081; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.